Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients

This trial tests a new gout drug called AR882 combined with a xanthine oxidase inhibitor (a standard gout medication) in people who had previously tried and failed treatment with uricase (a powerful enzyme-based gout therapy). The goal is to lower uric acid levels and reduce gout symptoms like tophi (hard lumps of uric acid crystals under the skin). **You may be eligible if...** - You have a history of uncontrolled gout - You have at least one visible tophus (lump under the skin caused by uric acid crystals) - Your last uricase treatment was at least 3 months ago - You weigh at least 50 kg (110 lbs) and have acceptable kidney function **You may NOT be eligible if...** - You have had cancer in the past 5 years (minor skin cancers excepted) - You are pregnant or breastfeeding - You have had symptomatic kidney stones in the past 6 months - You have received a uricase drug (pegloticase, rasburicase) within the last 3 months Talk to your doctor to see if this trial is right for you.